Kevin Grogan

Executive Summary The UK group remains confident that the scale of the US opioid epidemic, driven by misuse of fentanyl, still represents

Executive Summary Deal Snapshot: Ipsen has entered into a global licensing agreement with Foreseen Biotechnology potentially worth up

Executive Summary The German biotech has unveiled a $150m series D financing round to support a “broad Phase IIb development program for

Executive Summary Novartis leads the fight against malaria, pioneering innovative studies in sub-Saharan Africa to combat parasite resistance to current antimalarials.

Executive Summary Two older drugs – Cosentyx and Entresto – continue to drive growth at the Swiss giant, while Leqvio is finally making its mark on the sales front.

Executive Summary The head of the Basel-headquartered giant is no fan of bidding wars when it comes to dealmaking.

Executive Summary The Barcelona-headquartered group's Lilly-partnered atopic dermatitis drug is enjoying a decent launch in Germany and reimbursement has just been secured in the UK.

Executive Summary Deal Snapshot: Degrading rather than inhibiting a target protein has emerged as one of the most promising approaches in

Executive Summary The UK major has raised its full-year sales and earnings forecast on strong demand in the second quarter for its cancer, rare disease and cardiovascular medicines.

Executive Summary The Paris-based group has inked five external deals already this year, this time paying $111m to get access internationally